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ABSTRACT
Introduction: The objective of this study is to
evaluate the influence of repeated intraocular
dexamethasone implant (Ozurdex) injections
on metabolic control in type 2 diabetic patients.
Methods: Retrospective study of 165 type 2
diabetic patients starting Ozurdex treatment
who received no less than three consecutive
injections. Glycated hemoglobin (HbA1c),
serum creatinine, total cholesterol, high-density
lipoprotein (HDL) cholesterol, low-density
lipoprotein (LDL) cholesterol, and triglycerides
(TGs) were evaluated during 15 months of fol-
low-up after Ozurdex treatment onset.
Results: Fifty-seven patients met inclusion crite-
ria. Mean baseline values for HbA1c, creatinine,
total cholesterol, HDL cholesterol, and TGs before
treatment (7.1%, 1.3, 176.7, 51.1, and 125.6 mg/
dl, respectively) were similar to mean values after
Ozurdex onset (Wilcoxon test p values were 0.68,
0.41, 0.06, 0.87, and 0.33, respectively) and
remained stable during the follow-up period.
Mean LDL cholesterol levels increased slightly
after Ozurdex treatment onset (90.1 vs 88.2 mg/
dl, p= 0.04) but after 15 months of follow-up
they had returned to baseline values. Transient
increase in LDL cholesterol was remarkable in the
group of 24 bilaterally treated patients (96.8 vs
88.4 mg/dl, p= 0.03). A third of these patients
increased their baseline LDL values by more than
20%. Even with continuous injections of Ozur-
dex, LDL cholesterol levels also declined back to
baseline by month 15.
Conclusion: Ozurdex injections had no influ-
ence on HbA1c or renal function. Lipid profile
changes were mild and transient. However, a
significant temporary increase has been found
in LDL cholesterol levels in patients receiving
simultaneous bilateral injections. Lipid levels
should be monitored in patients starting with
bilateral Ozurdex injections especially in those
with recent history of acute myocardial
infarction.
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INTRODUCTION
Diabetic macular edema (DME) is the leading
cause of visual impairment in diabetic type 2
patients [1]. Two groups of intraocular drugs are
currently used for the treatment of DME:
anti-vascular endothelial growth factor (VEGF)
agents [2] and corticosteroids [3]. Four of these
drugs are approved for intraocular use: ranibi-
zumab (Lucentis, Novartis, Basel, Switzerland),
aflibercept (Eylea, Bayer Pharma, Berlin, Ger-
many), fluocinolone acetonide implant (Ilu-
vien, Alimera Sciences Inc., Alpharetta, GA,
USA), and dexamethasone (DEX) implant
(Ozurdex, Allergan Inc., Irvine, CA, USA).
The systemic safety profile is one of the main
concerns about anti-VEGF drugs. Serious
adverse events such as myocardial infarction,
stroke, arteriothrombotic events, and serious
hemorrhage have been described among others
[4]. No systemic side effects have been reported
related to Ozurdex implant injection so far [5],
and safety parameter assessments tend to
include local side effects exclusively, such as
cataract development and intraocular pressure
rise [3, 5–8].
Classic systemic effects of oral corticosteroids
include increase in serum insulin and glucose
levels, decrease in insulin-mediated glucose
uptake [9, 10], and dyslipidemia, including
increased serum levels of triglycerides (TGs),
low-density lipoprotein (LDL) cholesterol, and
high-density lipoprotein (HDL) cholesterol [11].
These parameters are extremely important for
cardiovascular risk of diabetic patients and have
a deep impact on their medium and long-term
survival [12, 13].
Ophthalmic local routes of corticosteroid
administration, such as peribulbar injection,
lead to significant systemic levels as demon-
strated in previous studies [14–18]; for instance,
5 mg of dexamethasone administered peribul-
barly is biologically equivalent to 50 mg of
orally administered prednisone [14]. Ozurdex is
a biodegradable sustained-release DEX implant,
delivered in the vitreous body. However, with
intravitreal 0.7-mg Ozurdex implant, dexam-
ethasone can reach plasma concentrations of
1.11 ng/ml, and it can still be detected in the
study subjects even 2 months after the intrav-
itreal injection [19]. DME is a chronic entity and
may need reinjections with an interval dosage
regimen below 6 months. Whether or not
repeated DEX-implant injections may alter
metabolic control in diabetic patients has not
been previously investigated.
The purpose of the present study was to
assess the impact of repeated Ozurdex injec-
tions on systemic parameters of type 2 diabetic
patients in real practice. This is, to our knowl-
edge, the first study to address this issue.
METHODS
Medical records from all patients starting
Ozurdex treatment at the Ophthalmology Ser-
vice, San Carlos University Hospital, between
January 2013 and January 2015 were retrospec-
tively reviewed. The following inclusion criteria
were applied: type 2 diabetic patients diagnosed
with macular edema treated with no less than
three consecutive Ozurdex injections, interval
between retreatments ranging from 4 to
6 months, and adequate systemic follow-up
before and after Ozurdex (at least medical revi-
sions every 6 months). Systemic parameters
evaluated were glycated hemoglobin (HbA1c),
serum creatinine, total cholesterol, HDL
cholesterol, LDL cholesterol, and TGs. Patients
with high HbA1c levels were not excluded from
the study. To ensure representative basal values
of these parameters, only those patients with at
least three complete fasting blood tests available
(18, 12, and 6 months) before Ozurdex were
considered eligible. After initiation of Ozurdex
treatments, blood tests performed at month 3,
month 9, and month 15 were recorded (Fig. 1).
Those blood tests performed during hospital-
ization were discarded to avoid acute-phase
non-representative changes. Tendency graphs
were created for every patient in search of pre-
defined response patterns. Exclusion criteria
were treatment with systemic corticosteroids,
change in systemic treatment 2 years before
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Ozurdex, intravitreal anti-VEGF injections
within 6 months prior to January 2013, and
Ozurdex retreatment interval below 4 months.
The metabolic statuses of patients were assessed
on the basis of blood tests performed before
starting Ozurdex treatment and those with
remarkable oscillations in the evaluated sys-
temic parameters were excluded.
The following data were extracted from the
medical records of the patients: age (years),
gender, systemic treatment, prior cataract sur-
gery, affected eye (right, left, or both), basal best
corrected visual acuity (measured with the Early
Treatment Diabetic Retinopathy Study (ETDRS)
method, an optotype with letters increasing in
size from 1 to 100), and cause of macular edema
(DME; retinal vein occlusion). Optic coherence
tomography (Spectralis; Heidelberg Engineering
GmbH, Heidelberg, Germany) was recorded at
every visit.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation (insti-
tutional and national) and with the Helsinki
Declaration of 1964, as revised in 2013.
Informed consent was not obtained from
patients because this is a retrospective study of
records. The study protocol was approved by the
institutional review board of our center (San
Carlos Clinical Hospital, Madrid, Spain).
Statistical Analysis
Analyses were performed by using SPSS 20 (IBM
SPSS, Chicago, IL, USA). Normally distributed
data were expressed as mean and standard
deviation (SD), and Student’s paired t test was
used to compare systemic parameters before
and after DEX treatment. Skewed data are
expressed as medians and quartiles, and Wil-
coxon’s test was used to compare values before
and after treatment. Spearman correlation
coefficient was calculated for the number of
injections and change in systemic variables. To
investigate if bilateral treatment had a greater
impact on systemic variables compared to uni-
lateral treatment, the Mann–Whitney test was
used. The three blood tests used for every
patient before Ozurdex treatment were consid-
ered as a mean value. The three blood tests
performed during Ozurdex treatments were
considered as a mean and also separately for
comparison with baseline status, searching for
transient changes that might go unnoticed
because of a regression toward mean values. A
p value less than 0.05 was considered statisti-
cally significant.
RESULTS
A total of 165 type 2 diabetic patients started
Ozurdex treatment during the study period.
Fifty-seven (34.5%) patients met study criteria.
The main exclusion criterion was lack of peri-
odic complete blood tests performed. Demo-
graphic data are shown in Table 1. Mean age
was 72.4 years (SD 10.4). Thirty-three patients
were male (58%). Thirty-nine subjects (68.4%)
were followed by an endocrinologist. Twenty-
nine (50.8%) patients were on insulin therapy
and the remaining (49.2%) were taking oral
antidiabetic drugs. At the end of the follow-up,
these percentages were stable but three patients
in the DME group had their oral antidiabetic
medication changed (from metformin to met-
formin in association with sitagliptin in order to
better control their HbA1c). The cause of the
Fig. 1 Chronological scheme of Ozurdex injections (dou-
ble line) and blood tests (stars) before and after treatment
in this study. To minimize inﬂuence of possible variability
in systemic parameters on baseline conditions three
representative blood tests performed at 18, 12, and
6 months before the ﬁrst Ozurdex implant were evaluated
and mean values calculated for each recorded variable were
considered as baseline values
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macular edema was retinal vein occlusion
(RVO) in 21 of our diabetic patients (36.8%) and
DME in 36 patients (63.2%). Twenty-four
patients (42.1%) received bilateral Ozurdex
injections. During the study period, a mean of
5.3 injections (SD 2.4) were used per patient.
Mean visual acuity was 46.1 ETDRS letters (SD
20.3) before treatment and 57.6 (SD 14.9) dur-
ing the peak effect after treatment. No patient
lost more than 15 letters during study time and
26 patients (45.6%) gained more than 15 letters.
Increased intraocular pressure after treatment
was reported in 12 patients (21%).
Metabolic status before and after Ozurdex
treatment onset was compared. To reduce vari-
ability of baseline conditions, the mean value of
each recorded variable was calculated from the
blood tests performed at months 18, 12, and 6
before the first Ozurdex injection and consid-
ered as baseline value for every parameter.
Table 2 shows HbA1c, creatinine, total choles-
terol, HDL cholesterol, LDL cholesterol, and TG
levels before and after Ozurdex treatment.
Values of systemic parameters are displayed for
the whole group of diabetic patients and also for
both subgroups of patients with DME or RVO.
In the entire cohort, mean baseline HbA1c was
7.1% (SD 1.2, range 5.3–11.2). In the first blood
test recorded for the study after Ozurdex treat-
ment onset, mean HbA1c value was 7.2% (SD
1.3, range 5.2–11.3). Wilcoxon tests showed no
significant differences compared to baseline
(p = 0.68). Thirty-three patients (57.8%) had
increased HbA1c levels with a mean change of
0.4% (SD 0.4). Maximum change was 2% (one
patient). Lower HbA1c levels were found in
31.6% of patients while 10.5% remained
unchanged with respect to basal values. The
second blood test showed a mean HbA1c of
7.1% (SD 1.3, range 5.5–12.5) and the third one
showed a mean of 7.1% (SD 1.1, range 5.2–9.7).
Corresponding Wilcoxon tests showed no dif-
ferences between baseline and the periods
assessed (p values 0.43 and 0.74, respectively).
Patients receiving more than five injections in
our study were also assessed separately. Again,
no differences were found in HbA1c before and
after Ozurdex treatment. Likewise, DME and
RVO subgroups showed no significant differ-
ences in HbA1c levels at any time in the fol-
low-up as compared to their respective baseline
values (all p values above 0.05).
Overall, no significant changes were found
in the whole study group for creatinine, total
cholesterol, HDL cholesterol, or TGs at any
period of the follow-up. LDL cholesterol levels
increased slightly after Ozurdex treatment
onset, but this effect was no longer detectable at
the end of the follow-up period. Although sta-
tistically significant, variations in this
Table 1 Characteristics of the patients in the study
Parameter All patients,
N5 57
Diabetic macular
edema, N5 36
Macular edema secondary to
retinal vein occlusion, N5 21
p value
Age (years), mean
(median; SD; range)
72.4 (73.0; 10.4; 46–95) 69.9 (72; 9; 54–84) 76.8 (79; 11.2; 46–95) 0.01
Gender
Female 24 (42.1%) 14 (59%) 10 (44%) 0.35
Male 33 (57.9%) 22 (41%) 11 (55%)
Visual acuity at presentation
(ETDRS letters)
46.1 (50; 20.3; 1–75) 49.4 (50; 19.5; 1–75) 40.6 (50; 20.8; 1–70) 0.12
Number of injections
per subject
5.3 (5; 2.4; 3–10) 6.0 (5; 2.5; 3–10) 4.14 (4; 1.6; 3–10) 0.001
Bilateral treatment 24 (42.1%) 22 (61.1%) 2 (9.5%) 0.001
 Mann–Whitney test; p values refer to comparisons between the two subgroups of patients
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parameter are quantitatively low. The increase
in LDL cholesterol levels was pronounced in the
DME subgroup (92.4 vs 81.1 mg/dl; p = 0.03)
whereas no changes were apparent in the RVO
patients.
Table 3 shows further subset analysis of sys-
temic parameters in bilaterally treated patients
(24 subjects of the total cohort). Mean basal
HbA1c was 7.6% (SD 1.1, range 6.1–9.8). Mean
post treatment was 7.3% (SD 1.3, range
5.3–11.2). There was no effect on this parameter
after Ozurdex treatment (Wilcoxon p = 0.45) or
in the whole follow-up (p = 0.56, p = 0.17, and
p = 0.21). Again, no significant changes were
detected for creatinine, total cholesterol, HDL
cholesterol, or TGs levels at any time of the
follow-up (all p values above 0.05). However,
remarkable changes were observed in LDL
cholesterol. Overall, mean baseline values were
88.4 mg/dl (SD 26.5, range 17–129) whereas
3 months after DEX implant, levels increased to
96.8 mg/dl (SD 33.6, range 24–165). The differ-
ence is significant (p = 0.03) and corresponds to
a 9.5% mean increase. Thirty-four percent of
the bilaterally treated patients increased their
LDL cholesterol levels more than 20% and half
of these were by more than 40% compared to
baseline values. This effect was transient
because in the third blood test after Ozurdex
treatment, LDL cholesterol values had returned
to basal levels (Fig. 2).
DISCUSSION
Our study shows that repeated Ozurdex injec-
tions had no influence on serum levels of
HbA1c or creatinine, nor on serum lipid profile
in type 2 diabetic patients. However, bilateral
simultaneous injections induced a transient
increase in LDL cholesterol levels.
There are no published studies on the phar-
macokinetics of Ozurdex implants in the
human eye. Systemic exposure was measured
during the two pivotal phase III studies [20]. In
5% of the subjects treated with 0.35-mg Ozur-
dex implant, plasma dexamethasone levels were
above the limit of quantitation of the test used
for measurement (0.05 ng/ml). For subjects
treated with 0.7-mg implant (unilateral
injection), this percentage rose to 13.7% [21].
Bilateral implant injection is routinely per-
formed as DME is often a bilateral condition;
thus, it is reasonable to think that systemic
exposure would be higher in these cases. In a
study performed on monkeys [19] with 0.7-mg
Ozurdex implants, a biphasic release pattern
was observed in treated eyes with peak levels of
the drug over the 2 months after administration
and continued releasing activity at decreasing
doses for 6 months. Mean maximum concen-
tration of dexamethasone in plasma was
1.11 ng/ml (range 0.99–1.22), and levels were
detectable up to 60 days. This concentration
could be clinically relevant, as maximum sup-
pression of the hypothalamic–pituitary–adrenal
axis occurs in humans at plasma concentrations
of 5 ng/ml and above [22].
Experimental administration of glucocorti-
coids increases plasma free fatty acid (FFA)
availability in the systemic circulation [23–25].
Increased plasma FFA availability can lead to
ectopic fat deposition in the liver and skeletal
muscle, attenuation of hepatic and skeletal
muscle insulin action (resulting in hyper-
glycemia and hyperinsulinemia), and stimula-
tion of hepatic very low-density lipoprotein
(VLDL) secretion and hypertriglyceridemia [23].
Hyperinsulinemia induces cardiac hypertrophy
and hyperglycemia mediates cardiac injury
through the generation of reactive oxygen spe-
cies [13]. This is especially relevant considering
the target population for Ozurdex treatment in
our study, diabetic patients, already at risk for
cardiovascular events.
Biological effects of dexamethasone can be
achieved regardless of the route of administra-
tion used. Thus, it has been shown that topical
administration of 0.1% dexamethasone (50 ll)
to male rats three times daily for 4 weeks
increased plasma total cholesterol threefold and
significantly reduced creatinine levels when
compared to sham-treated rats [26].
In the 3-year, randomized trial of Ozurdex in
DME (MEAD study) systemic safety issues were
mentioned [3]. HbA1c appeared to increase
progressively, and mean glomerular filtration
rates decreased during the study, but mean
values, standard deviations, or comparative
statistics were not presented. Our study was
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carefully designed to be able to detect changes
in systemic parameters. To avoid influence of
variability in HbA1c in pretreatment status,
three representative (and not overlapped) val-
ues from 18 months before Ozurdex treatment
were used. Only blood tests performed after
3 months from injection onset were considered,
because of red blood cell turnover (average
120 days [27]). Careful selection of blood tests
was applied, discarding those performed during
hospitalization. Three values during follow-up
were recorded to be able to detect transient
changes that might be regulated by compen-
satory mechanisms and camouflaged in average
analysis. As an example of this, in Table 2, LDL
cholesterol values increase during the first and
second blood tests after Ozurdex injections were
started (p values less than 0.05); however, in the
third blood test they are decreased. As a result,
comparison between pre- and post-treatment
finds no significant changes, because of regres-
sion towards the mean value.
Although no specific study has addressed the
different systemic profile of diabetic patients
with DME and RVO, we found that RVO
patients tended to be older and their glycemic
control better than DME patients. Interestingly,
no significant differences between both groups
were found in baseline total cholesterol
(p = 0.06), HDL cholesterol (p = 0.16), LDL
cholesterol (p = 0.35), TGs (p = 0.15), or crea-
tinine (p = 0.6), but Ozurdex treatment seemed
to induce changes of LDL cholesterol levels in
the DME group and not in the RVO patients.
Reasonably, the number of injections tended to
be higher in DME patients because RVO was
unilateral in almost all the cases included. Thus,
bilaterally treated patients were also considered
separately.
In patients receiving simultaneous bilateral
injections, LDL cholesterol values increased
significantly during short-term follow-up (88.4
vs 96.8 mg/dl , p = 0.03). Recommended LDL
cholesterol values for diabetic patients are less
than 100 mg/dl and less than 70 mg/dl if his-
tory of myocardial infarction is present [28].
After acute infarction, LDL cholesterol is also a
marker of systemic inflammation and has been
related to further destabilization of vascular
plaques [29]. Controlled levels of LDL choles-
terol are advisable, especially in the first
6 months after acute infarction, to prevent
recurrences and comorbidities [30]. Therefore,
and even when the systemic safety profile
would make Ozurdex preferable above anti-
VEGF drugs in this scenario, it would be advis-
able to monitor lipid levels after onset of bilat-
eral Ozurdex injections, especially in the first
6 months after acute myocardial infarction and
in those patients with pre-existing altered LDL
cholesterol levels.
A limitation of this study is the modest
sample size. Because of its retrospective nature,
the systemic parameters analyzed were restric-
ted to those reported on medical charts of the
patients included for analysis. Also, as certain
periods were selected for follow-up, we detected
a transient increase, but it is not possible to
know the real maximum level of LDL choles-
terol, and when that maximum is reached. On
the other hand, our population showed an
appropriate baseline metabolic control on
average as a result of the high percentage of
patients under monitoring by endocrinologists
(68.4%). This may represent a potential bias and
thus caution is necessary when extrapolating
these results to a broader population. The
increase in LDL cholesterol found in our study
might be exacerbated in a diabetic population
with poorer metabolic control. Future studies
with shorter interval between blood tests,
increased population size studied, and wider
range of diabetes management are needed to
further investigate these issues.
Fig. 2 Serum LDL cholesterol levels in patients treated
with bilateral Ozurdex injections. Mean values and
standard error are represented. *Signiﬁcantly different
from baseline value, p = 0.03
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CONCLUSIONS
Systemic effects of repeated intravitreal Ozurdex
injections assessed in this study are slight and
transient. However, caution must be exercised
in patients receiving bilateral Ozurdex injec-
tions if LDL cholesterol levels are not controlled
in advance.
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